Table 3

Cox regression analysis of immunohistochemistry signature score and clinicopathological covariates with disease-specific survival in the Guangzhou cohort

 Univariate analysisMultivariate analysis
HR (95% CI)p ValueHR (95% CI)p Value
Signature score (high-risk vs low-risk)3.54 (2.30 to 5.43)<0.0013.53 (2.13 to 5.84)<0.001
TNM stage (III vs I+II)1.87 (1.22 to 2.87)0.0041.63 (0.99 to 2.66)0.053
Differentiation grade (poorly vs well+moderately)1.59 (0.82 to 3.07)0.1711.97 (0.87 to 4.44)0.104
Adjuvant chemotherapy (yes vs No)0.89 (0.54 to 1.47)0.6421.05 (0.60 to 1.84)0.864
Age (≥50 vs <50 years)1.01 (0.61 to 1.67)0.9721.34 (0.75 to 2.41)0.327
Sex (men vs women)1.03 (0.67 to 1.58)0.8851.04 (0.64 to 1.69)0.882
Disease location (rectum vs colon)1.82 (1.15 to 2.88)0.0101.91 (1.12 to 3.25)0.017
Lymph nodes examined (≥12 vs <12)0.94 (0.60 to 1.46)0.7670.72 (0.43 to 1.21)0.216
Serum CEA (ng/ml) (≥5 vs <5)1.84 (1.16 to 2.92)0.0101.65 (0.98 to 2.79)0.059
Serum CA19-9 (U/ml) (≥37 vs <37)2.19 (1.33 to 3.62)0.0021.73 (0.99 to 3.03)0.054
  • CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; TNM, tumour to node to metastasis.